Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of September 2023. The filing, dated September 20, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is based in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
No material financial changes versus a prior comparable period are detailed in this filing text. The document solely references the issuance of a press release without summarizing its specific content or financial impact.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items within the text provided. These details are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not summarized here.
Key Facts for Investor Verification
- Verify the content of the press release dated September 20, 2023 (Exhibit 99.1), as it is the primary source of new information in this filing.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that this Form 6-K does not contain standalone financial data or operational updates.